Prevalence and distribution of human papillomavirus genotypes in Chinese women between 1991 and 2016: A systematic review.

BACKGROUND Human papillomavirus (HPV) associated cervical cancer is one of the most common cancers and ranked as the eighth most common killer for Chinese women. A dozen of HPV vaccines are being developed in China without a solid China-specific distribution of carcinogenic HPV types, thus, we performed this systematic review to explore the China-specific spectrum of high-risk types causing cancer. METHODS Studies on HPV infection among Chinese women were searched. All retrieved articles were screened and reviewed by a standardized algorithm. Distribution of carcinogenic HPV types and age-specific prevalence were analyzed using random-effects model. RESULTS A total of 303 articles were included in the final analysis. The top 10 common HPV types detected in ICC patients, in descending order of frequency, were HPV 16 (62.5%), 18 (12.4%), 58 (8.6%), 52 (5.7%), 33 (4.6%), 31 (3.5%), 55 (2.4%), 68 (2.4%), 53 (2.2%) and 45 (2.0%) respectively. Similar spectrum was found in women with precancer. The prevalence of HPV infection peaked between 20 and 24 years with a rate of 24.3%, thereafter declined substantially and stabilized at middle-ages. Compared to women living in the developed provinces, the second peak was observed among women aged 45-55 years in less developed regions. CONCLUSION In general, the spectrum of HPV types in women with precancer/cancer and the pattern of age-specific prevalence were consistent with that of elsewhere worldwide. However, some distinguished characteristics could also be concluded, and these imprinting should be considered and integrated when developing vaccines and strategy for disease control in China.

[1]  E. Pirog,et al.  Human papillomavirus prevalence and type‐distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study , 2015, International journal of cancer.

[2]  C. Castelo-Branco,et al.  Menopause and aging: changes in the immune system--a review. , 2010, Maturitas.

[3]  V. Ramakrishnan,et al.  Global Variation of Human Papillomavirus Genotypes and Selected Genes Involved in Cervical Malignancies. , 2016, Annals of global health.

[4]  N. Grabe,et al.  Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer , 2014, The Journal of pathology.

[5]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[6]  J. Kaufman,et al.  Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination , 2016, PloS one.

[7]  W. Quint,et al.  Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub‐Saharan Africa , 2014, International journal of cancer.

[8]  P. Chan,et al.  Meta-Analysis on Prevalence and Attribution of Human Papillomavirus Types 52 and 58 in Cervical Neoplasia Worldwide , 2014, PloS one.

[9]  M. Poljak,et al.  Molecular methods for identification and characterization of novel papillomaviruses. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[11]  F. Guo,et al.  Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years) , 2015, Human vaccines & immunotherapeutics.

[12]  M. Plummer,et al.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.

[13]  N. Muñoz,et al.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. , 2007, The Lancet. Infectious diseases.

[14]  A. Thiébaut,et al.  Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies , 2013, BMC Infectious Diseases.

[15]  Y. Qiao,et al.  A prospective study of age trends of high-risk human papillomavirus infection in rural China , 2014, BMC Infectious Diseases.

[16]  Wanqing Chen,et al.  Report of cancer incidence and mortality in China, 2010. , 2014, Annals of translational medicine.

[17]  M. Lehtinen,et al.  Occurrence of vaccine and non‐vaccine human papillomavirus types in adolescent Finnish females 4 years post‐vaccination , 2012, International Journal of Cancer.

[18]  S. Weyers,et al.  Evaluation of the clinical significance of human papillomavirus (HPV) 53. , 2015, European journal of obstetrics, gynecology, and reproductive biology.

[19]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[20]  E. J. Mayeaux,et al.  Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. , 2015, Gynecologic oncology.

[21]  C. Wheeler,et al.  Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials , 2017, Journal of the National Cancer Institute.

[22]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[23]  Susan Westlake,et al.  Report: Cancer incidence and mortality , 2008 .

[24]  Chen Wan-qin,et al.  Report of Cancer Incidence and Mortality in China,2011 , 2015 .

[25]  Helen Trottier,et al.  The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.

[26]  Human papillomavirus vaccines: WHO position paper, May 2017. , 2017, Releve epidemiologique hebdomadaire.